Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.

Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.
复制标题

DOI:
10.1016/j.coviro.2021.06.008
复制
发表时间:
2021-10
影响因子:
5.9
通讯作者:
Meibohm B
Meibohm B
中科院分区:
医学2区
文献类型:
--
作者:
Jonsson CB;Golden JE;Meibohm B

文献摘要

参考文献

相似文献

鉴于接种疫苗的犹豫不决、令人担忧的病毒变种的出现、接种无效或无法获得疫苗的易感人群以及冠状病毒病2019年(新冠肺炎)持续存在的可能性,有效的直接作用抗病毒药物(DAA)的管道仍然是解决当前大流行的关键缺口。自疫情爆发以来,全球在小分子药物发现方面的努力主要集中在FDA批准的药物的测试上,以加快住院患者临床试验的评估。由于80%的SARS-CoV-2阳性人群在早期有无症状到轻度新冠肺炎的症状,DAA对缩短传播、症状持续时间和隔离时间将有巨大的好处。我们重点介绍了一些临床试验中最有前途的DAA,并讨论了如何应对新的小分子发现的挑战和陷阱,从而加速新的、安全的和口服的DAA的发展。
A pipeline of effective direct-acting antivirals (DAAs) remains a critical gap in addressing the current pandemic given vaccination hesitancy, the emergence of viral variants of concern, susceptible populations for which vaccination is ineffective or unavailable, and the possibility that coronavirus disease 2019 (COVID-19) is here to stay. Since the start of the pandemic, global efforts in small molecule drug discovery have focused largely on testing of FDA-approved drugs to accelerate evaluation in clinical trials in hospitalized patients. With 80% of the population who test positive for SARS-CoV-2 having asymptomatic to mild COVID-19, early stage, DAAs would be of enormous benefit to reduce spread, duration of symptoms and quarantine length. We highlight a few of the most promising DAAs in clinical trials and discuss considerations in how to navigate the challenges and pitfalls of novel small molecule discovery and thereby accelerate the advancement of new, safe, and oral DAAs.
DOI: 10.1073/pnas.2014441117
发表时间: 2020-10-27
影响因子: 11.1
作者:
Kaptein SJF;Jacobs S;Langendries L;Seldeslachts L;Ter Horst S;Liesenborghs L;Hens B;Vergote V;Heylen E;Barthelemy K;Maas E;De Keyzer C;Bervoets L;Rymenants J;Van Buyten T;Zhang X;Abdelnabi R;Pang J;Williams R;Thibaut HJ;Dallmeier K;Boudewijns R;Wouters J;Augustijns P;Verougstraete N;Cawthorne C;Breuer J;Solas C;Weynand B;Annaert P;Spriet I;Vande Velde G;Neyts J;Rocha-Pereira J;Delang L
通讯作者: Delang L
DOI: 10.1038/s41467-021-21992-w
发表时间: 2021-03-19
影响因子: 16.6
作者:
Driouich JS;Cochin M;Lingas G;Moureau G;Touret F;Petit PR;Piorkowski G;Barthélémy K;Laprie C;Coutard B;Guedj J;de Lamballerie X;Solas C;Nougairède A
通讯作者: Nougairède A
DOI: 10.1016/j.antiviral.2013.09.015
发表时间: 2013-11
期刊: ANTIVIRAL RESEARCH
影响因子: 7.6
作者:
Furuta, Yousuke;Gowen, Brian B.;Takahashi, Kazumi;Shiraki, Kimiyasu;Smee, Donald F.;Barnard, Dale L.
通讯作者: Barnard, Dale L.
DOI: 10.1038/s41586-021-03553-9
发表时间: 2021-04-22
期刊: NATURE
影响因子: 64.8
作者:
Al-Aly, Ziyad;Xie, Yan;Bowe, Benjamin
通讯作者: Bowe, Benjamin
DOI: 10.1016/j.antiviral.2014.12.015
发表时间: 2015-03
期刊: Antiviral research
影响因子: 7.6
作者:
Báez-Santos YM;St John SE;Mesecar AD
通讯作者: Mesecar AD